CG
CHRS icon

Cutler Group’s Coherus Oncology CHRS Stock Holding History

Cutler Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$8K – 3842
2023
Q2 		$8K Buy
+2,000
New +$11.8K ﹤0.01% 2355
2020
Q1 		– Sell
-300
Closed -$5.54K – 4068
2019
Q4 		$5K Sell
300
-1,300
-81% -$24K ﹤0.01% 3018
2019
Q3 		$32K Buy
+1,600
New +$32K ﹤0.01% 1838
2018
Q4 		– Sell
-1,800
Closed -$20.8K – 3984
2018
Q3 		$29K Buy
1,800
+1,700
+1,700% +$30.1K ﹤0.01% 1986
2018
Q2 		$1K Sell
100
-6,600
-99% -$94.5K ﹤0.01% 3774
2018
Q1 		$74K Sell
6,700
-1,104
-14% -$12.1K 0.01% 1392
2017
Q4 		$68K Sell
7,804
-7,668
-50% -$82.1K ﹤0.01% 1637
2017
Q3 		$206K Buy
15,472
+1,088
+8% +$14.4K 0.01% 1158
2017
Q2 		$206K Buy
14,384
+12,584
+699% +$242K 0.01% 1254
2017
Q1 		$38K Sell
1,800
-5,721
-76% -$141K ﹤0.01% 2666
2016
Q4 		$211K Buy
7,521
+3,101
+70% +$86.8K 0.01% 1259
2016
Q3 		$118K Buy
+4,420
New +$121K 0.01% 1685

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Cutler Group's CHRS Position: Q3 2023 in Review

Cutler Group sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 2,000 shares — an estimated $8K sold.

Cutler Group first reported a position in CHRS in Q3 2016 and held it in 12 quarters. The position peaked at $211K in Q4 2016. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Cutler Group reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 Coherus Oncology shares in Q3 2023, an estimated $8K.
  • Cutler Group first reported a position in Coherus Oncology in Q3 2016 and held it in 12 quarters.
  • Cutler Group's Coherus Oncology position peaked at $211K in Q4 2016.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.